X
Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
Details:
Under the collaboration, Nona Biosciences will integrate GeneQuantum's exclusive and innovative iLDC and iGDC platforms, with its Harbour Mice® platform and cutting-edge technologies, to advance the early discovery of next-generation bioconjugates.
Lead Product(s): Bioconjugate
Therapeutic Area: Technology Product Name: Undisclosed
Highest Development Status: DiscoveryProduct Type: Large molecule
Partner/Sponsor/Collaborator: Nona Biosciences
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Collaboration November 13, 2023
Details:
Under the agreement, GeneQuantum will provide InxMed with its globally leading technologies in site-specific glycan conjugation, stable linker small molecule technology, and intelligent continuous conjugation production platform for developing innovative ADC drugs.
Lead Product(s): Antibody-drug Conjugate
Therapeutic Area: Oncology Product Name: Undisclosed
Highest Development Status: DiscoveryProduct Type: Large molecule
Partner/Sponsor/Collaborator: InxMed
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Collaboration July 17, 2023
Details:
Under the collaboration, GeneQuantum and Aimed Bio aims to jointly develop up to five new antibody-drug conjugate drugs to address unmet clinical needs for patients with severe brain diseases.
Lead Product(s): Antibody-drug Conjugate
Therapeutic Area: Oncology Product Name: Undisclosed
Highest Development Status: DiscoveryProduct Type: Large molecule
Partner/Sponsor/Collaborator: Aimed Bio
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Expanded Collaboration July 06, 2023
Details:
Under the partnership, GQ will leverage TOBio's expertise in CMC and commercial manufacturing to advance its pharmaceutical research on antibody-drug conjugate (ADC) products by using its innovative conjugation technology.
Lead Product(s): Antibody-drug Conjugate
Therapeutic Area: Technology Product Name: Undisclosed
Highest Development Status: DiscoveryProduct Type: Large molecule
Recipient: Thousand Oaks Biologics
Deal Size: $28.3 million Upfront Cash: Undisclosed
Deal Type: Partnership May 22, 2023
Details:
Under the terms of the agreement, Pyramid Biosciences will develop and commercialize GQ1010, a potential best-in-class antibody drug conjugate (ADC) targeting TROP2, worldwide except for Greater China, using GeneQuantum's proprietary technology.
Lead Product(s): GQ1010
Therapeutic Area: Oncology Product Name: GQ1010
Highest Development Status: PreclinicalProduct Type: Large molecule
Recipient: Pyramid Bio
Deal Size: $1,020.0 million Upfront Cash: $20.0 million
Deal Type: Licensing Agreement April 13, 2023
Details:
GQ1005, is a HER2 targeting ADC with an excellent bystander killing effect, and the stable linker technology have demonstrated the advantages through several IND enabled drug candidates.
Lead Product(s): GQ1005
Therapeutic Area: Oncology Product Name: GQ1005
Highest Development Status: IND EnablingProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable May 15, 2022
Details:
The collaborating ADC is a first-in-class asset AMB302, with highly differentiated antibody against a unique target, a stable linker design and a novel payload with a strong by-stander killing effect.
Lead Product(s): AMB302
Therapeutic Area: Oncology Product Name: AMB302
Highest Development Status: PreclinicalProduct Type: Large molecule
Partner/Sponsor/Collaborator: Aimed Bio
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Collaboration April 19, 2022
Details:
Both companies signed a co-development agreement for antibody immune agonist conjugate (AIAC), GQ1007. GQ1007 is a new type of antibody-drug conjugate which has achieves strong and lasting anti-tumor effect, overcomes the low response rate of PD-1 antibody in immunotherapy.
Lead Product(s): GQ1007
Therapeutic Area: Oncology Product Name: GQ1007
Highest Development Status: IND EnablingProduct Type: Large molecule
Partner/Sponsor/Collaborator: BrighGene Biomedical
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Collaboration September 05, 2021
Details:
GQ1001 is an antibody drug conjugate (ADC) that is currently in global multi-center clinical trial development for treatment of HER2+ solid tumor. GQ1001 was synthesized by site-specific conjugation of toxin DM1 to trastuzumab.
Lead Product(s): GQ1001
Therapeutic Area: Oncology Product Name: GQ1001
Highest Development Status: Phase IProduct Type: Large molecule
Partner/Sponsor/Collaborator: China Life Private Equity Investment
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Series C Financing May 19, 2021
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results] 
Market Place
